ILGEN Inc

March 27, 2020: ILGEN Inc. will discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.

  • Stage Product In Development
  • Industry Healthcare Services
  • Location Syracuse, NY, USA
  • Currency USD
  • Founded March 2016
  • Employees 3
  • Incorporation Type C-corp
  • Website ilgenbio.com

Company Summary

SARS-Cov-2 neutralizing therapeutic antibody will be developed using ILGEN's technology.
Our technology is protected by US patent issued in 2017. It allows us to search, detect, and develop first-in-class specific high-affinity, naturally occurring fully human antibodies and proteins for the vast majority of diseases.
We are looking for a modest investment for ambitious projects that we plan to commercialize in the near future.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free